(HealthDay News) — For patients with myocardial infarction (MI), treatment with beta blockers beyond one year after MI does not appear to reduce the risk for mortality or further MI, according to a study published online May 2 in Heart.
Divan Ishak, MD, from Uppsala University in Sweden, and colleagues conducted a nationwide cohort study involving 43,618 patients with MI between 2005 and 2016. Follow-up began one year after hospitalization (index date). Patients were categorized into two groups according to beta blocker treatment; 78.5% and 21.5% of patients received treatment and did not receive treatment, respectively, at the index date.
The researchers found that the unadjusted rate of primary outcome (composite of all-cause mortality, MI, unscheduled revascularization, and hospitalization for heart failure) was lower among those who received versus those who did not receive beta blocker treatment (3.8 versus 4.9 events per 100 person years; hazard ratio, 0.76; 95% confidence interval, 0.73 to 1.04). The risk for the primary outcome was not different according to beta blocker treatment after inverse propensity score weighting and multivariable adjustment (hazard ratio, 0.99; 95% confidence interval, 0.93 to 1.04). When censoring for beta blocker discontinuation or treatment switch during follow-up, findings were similar.
“Long-term beta blocker therapy was not associated with improved cardiovascular outcomes during median follow-up of 4.5 years,” the authors wrote. “These findings were consistent across individual secondary end points and across patient subgroups.”
Several authors disclosed financial ties to the pharmaceutical industry.
Related articles:
Beta blockers may reduce mortality in patients with heart disease and dementia: study
Sleep, not depression, may be top concern with beta blocker use: study
